Enveric Biosciences Highlights Results for EB-003 In PTSD Preclinical Model; Says Previously Reported Results Support Continued Development Of EB-003 For PTSD, Other Neuropsychiatric Condition

Enveric Biosciences today highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose (p < 0.05). These results indicate a rapid reduction in conditioned fear response in a validated preclinical model of post-traumatic stress disorder (PTSD).